Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty
Postoperative Pain
About this trial
This is an interventional treatment trial for Postoperative Pain
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18-80 years old
- American Society of Anesthesiology physical status I-III
- Primary total knee arthroplasty surgery under regional anesthesia
Exclusion Criteria:
- Chronic kidney disease (CKD) with eGFR < 60mL/min
- Contraindications for the use of spinal anesthesia or adductor canal block : infection, sepsis, evolutive neurological disease, coagulopathy, patient refusal.
- Chronic use of opioids (>30 mg daily morphine equivalent)
- Documented allergy to Hydromorphone, tramadol, celecoxib, ropivacaine, pregabalin, acetaminophen and/or ketorolac
- Patient weight < 50 kg or BMI > 40
- Severe cardiac disease
- Severe pulmonary disease
- Chronic use of monoamine oxydase inhibitors
- Pregnancy
- Inability to give informed consent
- Patient refusal
Sites / Locations
- Ciusss
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Group C
Group U
Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter. They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery
Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down. They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total